性别肯定乳房切除术后的增生性瘢痕:发生率与危险因素
本研究回顾性分析了2020至2024年241例接受双切口性别肯定乳房切除术的患者,评估增生性瘢痕的发生率及危险因素。结果显示增生性瘢痕发生率为16.6%,非白人种族和围手术期雄激素使用是显著危险因素。年龄、BMI、合并症、吸烟、既往乳房手术及切除重量未显示显著关联。
要点
- 双切口性别肯定乳房切除术后增生性瘢痕发生率为16.6%。
- 非白人种族与增生性瘢痕风险升高相关(OR 2.7)。
- 围手术期雄激素使用与增生性瘢痕风险升高相关(OR 2.6)。
核心结论
- 增生性瘢痕是性别肯定乳房切除术后常见并发症,非白人种族和雄激素治疗是显著危险因素。
研究设计与样本
- 回顾性研究,纳入2020至2024年241例双切口性别肯定乳房切除术患者,采用多变量回归分析。
主要发现
- 增生性瘢痕发生率为16.6%,其中50%接受皮质类固醇注射,5%接受瘢痕修整。
- 非白人种族增生性瘢痕发生率26.5% vs 14.1%(OR 2.7,95%CI 1.2-6.0,P=0.018)。
- 非白人种族需皮质类固醇注射率16.3% vs 6.3%(P=0.023),瘢痕修整率4.1% vs 0.0%(P=0.041)。
- 围手术期雄激素使用(68.5%患者)与增生性瘢痕发生率20.0% vs 9.2%(OR 2.6,95%CI 1.0-6.4,P=0.028)相关。
- 年龄、BMI、合并症、吸烟、既往乳房手术及切除重量不是显著危险因素。
临床怎么用
- 应告知患者个体化风险特征,高危患者可从早期预防和治疗干预中获益。
局限性
- 平均随访时间5.2±4.5个月,可能低估远期瘢痕发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gender-affirming mastectomy (GAM) is the most common gender-affirming operation. However, the double-incision technique involves long horizontal chest incisions, which may be prone to hypertrophic scarring (HS). Despite the potential functional and psychosocial morbidity of HS, limited research has investigated its occurrence in this patient population. This study evaluated the incidence and risk factors of HS following GAM. METHODS: A retrospective study was conducted of double-incision GAM patients from 2020 to 2024. Data included demographics, comorbidities, androgen therapy, postoperative complications including HS, corticosteroid injections, and scar revision. Multivariable regression was performed. RESULTS: A total of 241 patients were included. HS developed in 16.6%, of whom 50% underwent corticosteroid injections and 5% underwent scar revision. Non-White race was significantly associated with higher rates of HS (26.5% versus 14.1%; OR, 2.7; 95% CI, 1.2 to 6.0; P = 0.018), HS requiring corticosteroid injections (16.3% versus 6.3%; P = 0.023), and scar revision (4.1% versus 0.0%; P = 0.041). Perioperative androgen use (68.5% of patients) was significantly associated with higher rates of HS (20.0% versus 9.2%; OR, 2.6; 95% CI, 1.0 to 6.4; P = 0.028). Age, body mass index, comorbidities, nicotine use, previous breast surgery, and mastectomy weight were not significant risk factors. Average follow-up was 5.2 ± 4.5 months. CONCLUSIONS: HS is a common postoperative complication following GAM, with non-White race and androgen therapy identified as significant risk factors. Patients should be counseled regarding their individual risk profile. High-risk patients should benefit from early preventive and therapeutic interventions. Future research should investigate perioperative androgen management that balances optimal scarring outcomes and patients' broader gender-affirming goals.
引用
- Remy K, Plascevic J, Iwelumo K, et al. Beyond the Incision: Incidence and Risk Factors of Hypertrophic Scarring following Gender-Affirming Mastectomy. Plast Reconstr Surg. 2025. PMID: 41086392. doi:10.1097/PRS.0000000000012536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。